# Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

> **NCT00078234** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 25 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Oblimersen-rituximab-fludarabine

## Key facts

- **NCT ID:** NCT00078234
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2008-09
- **Final completion:** 2010-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078234, "Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00078234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*